Biotechnology

eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

November 13, 2025 4:30 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - plans to host a webinar at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended October 31, 2025. Michael Heltzen, CEO of eXoZymes, states, "Since our last quarterly update, we have worked diligently on maturing our core assets - both...

Read more

eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff

November 13, 2025 4:15 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced that co-founder of eXoZymes, Tyler Korman, PhD, has taken on the role of Chief Scientific Officer, while Amy Lunzer - an accomplished business, supply-chain, and operations executive - is appointed as Chief of Staff. CSO of eXoZymes, Tyler Korman, PhD, states, "I'm excited...

Read more

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

November 13, 2025 9:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced that the United States Patent and Trademark Office ("USPTO") has granted the company U.S. Patent No. 12,465,589, titled "Methods and Composition for Treating CNS Disorders." The patent covers the propriety...

Read more

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

November 13, 2025 8:45 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the third quarter 2025. "We are steadily building the foundation for potentially transformative progress in the oncology treatment paradigm as we advance our systemic DNase I program in combination with...

Read more

Lifeloc Reports Third Quarter 2025 Results

November 12, 2025 4:38 PM

Lifeloc Technologies, Inc. (OTC:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2025. Third Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.257 million in the third quarter of 2025, resulting in a quarterly net loss of $(263) thousand, or $(0.10) per diluted share. These results compare to net...

Read more

New Study From GENinCode Shows Polygenic Risk Scores Improve the Accuracy of Cardiovascular Disease Risk Prediction

November 12, 2025 7:15 AM

American Heart Association ("AHA") Conference 2025, GENinCode the predictive genetics company focused on the prevention of cardiovascular disease ("CVD"), announces the presentation by Kaiser Permanente of a major clinical utility study on CARDIO inCode-Score Polygenic Risk Score ("PRS") for the prevention of coronary heart disease ("CHD"). Cardiovascular disease ("CVD") is the leading cause of death in the US and worldwide with over 82 million...

Read more

Tex Cycle Accelerates Growth with 67% Revenue Surge in Q3 FY2025

November 11, 2025 10:35 PM

Tex Cycle Technology (M) Berhad ("Tex Cycle" or the "Group"), an established waste management and recycling solutions provider, today announced its financial results for the third quarter ended 30 September 2025 ("Q3 FY2025"). The Group recorded a revenue of RM17.7 million, representing a 67.0% increase year-on-year ("YoY") from RM10.6 million in the same quarter last year (Q3 FY2024), driven primarily by the newly acquired subsidiary, Meridian...

Read more

Repair Biotechnologies Presents Preclinical Data at American Heart Association's Scientific Sessions 2025 Showing Regression of Atherosclerotic Plaque With REP-0003 Treatment

November 11, 2025 9:00 AM

Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/) today announced the recent presentation of preclinical data at American Heart Association's (AHA) Scientific Sessions 2025, held from November 7th to 10th in New Orleans, Louisiana, supporting the ability of its drug REP-0003 to rapidly and safely reduce established atherosclerotic plaque. Repair Biotechnologies develops the REP-0003 therapy based on the proprietary...

Read more

Digital Earth Session at 2025 WSTDF Advances SDGs

November 11, 2025 2:30 AM

The Thematic Session on Digital Earth Supporting Sustainable Development convened during the 2025 World Science and Technology Development Forum (WSTDF) in Beijing on Tuesday, bringing together 70 leading figures and representatives from research institutes and universities of 19 countries and relevant UN agencies and international organizations to tackle the problems along niche opportunities brought by emerging science and technology trends,...

Read more

eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST

November 10, 2025 5:00 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Thursday, November 13, 2025 at 5:00 PM Eastern Time to discuss its results for the third quarter of 2025. Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review...

Read more

Athos Therapeutics and Xeptiva Therapeutics Announce Partnership to Discover Vaccine Biomarkers with the AthosOmics.AI Platform

November 10, 2025 11:00 AM

Athos Therapeutics, Inc. ("Athos"), an AI software and clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, announced a new partnership with Xeptiva, using "AthosOmics.AI," a novel and impactful AI data platform for analyzing omics data across industries. AthosOmics.AI brings multiple no-code, agentic AI software solutions to the growing field of...

Read more

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

November 10, 2025 9:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced that the Company will host a conference call and webcast on Monday, November 17, 2025, at 11:00 a.m. Eastern Time to review the Company's operational progress for the second quarter and mid-year period ended September 30, 2025. To...

Read more

Lir Life Sciences Corp. Formerly Blackbird Critical Metals Corp. Announces Closing of Acquisition of Lir Life Sciences Inc.

November 10, 2025 9:00 AM

Lir Life Sciences Corp. (CSE:SKNY) (formerly Blackbird Critical Metals Corp.) ("Lir Life Sciences" or the "Company") is pleased to announce, further to its news release dated August 14, 2025, that it has completed the acquisition (the "Transaction") of all of the issued and outstanding shares of Lir Life Sciences Inc. ("Lir Inc."), and that trading in the common shares of the Company resumed on the Canadian Securities Exchange (the "CSE") on...

Read more

BioInvent's BI-1910 Data Validates TNFR2 as a Novel Immunotherapy Approach in Advanced Solid Tumors: Phase 1 Data at SITC 2025

November 7, 2025 9:20 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced the presentation of Phase 1 clinical data for BI‑1910, a TNFR2 agonist antibody, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The data, presented in the poster titled "Preliminary Phase 1 results of...

Read more

ClearPoint Neuro Reports Third Quarter 2025 Results

November 6, 2025 4:55 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2025. Third Quarter Highlights Continued to provide supply, development, and strategic support to more than 60 active biopharma partners, including nine partner programs accepted for FDA expedited review, with...

Read more

ClearPoint Neuro Announces Agreement to Acquire IRRAS

November 6, 2025 4:50 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced the acquisition of San Diego based, IRRAS Holdings, Inc., a medical technology company focused on neurocritical care, with an emphasis on treatments for intracerebral hemorrhage, chronic subdural hematoma, and other conditions requiring intracranial fluid management....

Read more

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025

November 5, 2025 5:02 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will participate in the following investor conferences: 2025 UBS Global Healthcare Conference - Palm Beach Gardens, FL Presenting on Monday, November 10, 2025 2025 Stifel Healthcare Conference - New York, NY Presenting on Thursday, November 13, 2025 37th Annual Piper...

Read more

FluoGuide Strengthens Leadership to Advance Clinical Program and Regulatory Approval Strategy

November 5, 2025 11:50 AM

FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces changes to both its corporate management and Board of Directors to drive the Company's transition into the next phase of U.S. clinical development and regulatory approval. These changes bring strong, complementary development and commercial capabilities to the organization. Donna Haire appointed Chief Operating Officer...

Read more

FluoGuide Convenes an Extraordinary General Meeting

November 5, 2025 11:45 AM

FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") hereby invites shareholders to participate in an extraordinary general meeting to be held on 24 November at 10 AM CET at the Company's premises. To the shareholders of FluoGuide A/S Following the issuance of shares resolved by the Board of Directors on 3 November 2025, the board of directors proposes to reestablish the authorisation to issue up to nominal DKK 300,000 corresponding to...

Read more

Alligator Bioscience Presents New Data on Mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting

November 5, 2025 5:20 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of two abstracts accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, to be held 5-9 November 2025 in National Harbor, MD, USA. The mitazalimab abstract presents new data from the OPTIMIZE-1 trial in metastatic...

Read more